Publications

Presentations and Publications

July, 2024

May, 2024

October, 2023

7th Antifibrotic Drug Development Summit

October, 2023

Altered NKT cell populations in the airways of patients with IPF

September, 2023

Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis

May, 2020

Differential Activation of Unconventional T Cells, Including iNKT Cells, in Alcohol-Related Liver Disease.

February, 2019
American Journal of Physiology

Intestinal iNKT cells migrate to liver and contribute to hepatocyte apoptosis during alcoholic liver disease.

November, 2018

Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis.

September, 2018
Frontiers in Immunology

Complex Network of NKT Cell Subsets Controls Immune Homeostasis in Liver and Gut.

February, 2018
Gastroenterology

Sulfatide-mediated activation of type II natural killer T cells prevents hepatic ischemic reperfusion injury in mice.

February, 2017

Type II NKT Cells and Their Emerging Role in Health and Disease.

March, 2016
Cellular and Molecular Immunology

Invariant natural killer T cells contribute to chronic-plus-binge ethanol-mediated liver injury by promoting hepatic neutrophil infiltration.

April, 2015
Heptology

Inhibition of type I natural killer T cells by retinoids or following sulfatide-mediated activation of type II natural killer T cells attenuates alcoholic liver disease in mice. Heptology; April, 2015

November, 2014

Recognition of lysophosphatidylcholine by type II NKT cells and protection from an inflammatory liver disease.

September, 2013

NKT-cell subsets: promoters and protectors in inflammatory liver disease.

July, 2007
Journal of Clinical Investigation

Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease.

April, 2004
Journal of Experimental Medicine

Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide.